journal
Journals Expert Review of Clinical Phar...

Expert Review of Clinical Pharmacology

https://read.qxmd.com/read/38299560/pharmacokinetic-correlates-of-clinical-response-in-a-naturalistic-sample-of-escitalopram-treated-patients
#21
JOURNAL ARTICLE
Nicholas Kasperk, Ekkehard Haen, Christoph Hiemke, Thomas Frodl, Georgios Schoretsanitis, Michael Paulzen, Nazar Kuzo
OBJECTIVE: We assessed pharmacokinetic correlates of treatment response to escitalopram using a large therapeutic drug monitoring database. METHODS: A large naturalistic sample of patients receiving escitalopram was analyzed. Responders were defined as 'very much improved' or 'much improved' based on the Clinical Global Impression - Improvement score, CGI-I. We compared responders ( n  = 83) vs. non-responders ( n  = 388) with the primary outcome being the escitalopram plasma concentration and concentration corrected by the daily dose (C/D ratio)...
February 1, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38287694/influence-of-n-acetyltransferase-2-polymorphisms-and-clinical-variables-on-liver-function-profile-of-tuberculosis-patients
#22
JOURNAL ARTICLE
Levin Thomas, Arun Prasath Raju, Chaithra S, Shrivathsa Kulavalli, Muralidhar Varma, Chidananda Sanju Sv, Mithu Banerjee, Kavitha Saravu, Surulivelrajan Mallayasamy, Mahadev Rao
BACKGROUND: Single nucleotide polymorphisms (SNPs) in the N-acetyltransferase 2 (NAT2) gene as well as several other clinical factors can contribute to the elevation of liver function test values in tuberculosis (TB) patients receiving antitubercular therapy (ATT). RESEARCH DESIGN AND METHODS: A prospective study involving dynamic monitoring of the liver function tests among 130 TB patients from baseline to 98 days post ATT initiation, was undertaken to assess the influence of pharmacogenomic and clinical variables on the elevation of liver function test values...
January 29, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38275183/statin-related-neurocognitive-disorder-a-real-world-pharmacovigilance-study-based-on-the-fda-adverse-event-reporting-system
#23
JOURNAL ARTICLE
Min Xiao, Li Li, Weiwei Zhu, Fengbo Wu, Bin Wu
BACKGROUND: Concerns regarding statin-related neurocognitive disorders have emerged in recent years. However, previous studies have reported inconsistent results. We evaluated the association between statins and neurocognitive disorders using the FDA Adverse Event Reporting System (FAERS). RESEARCH DESIGN AND METHODS: Data from 2004 to 2022 were obtained from the FAERS database. After deduplication and standardization of drug names, we extracted neurocognitive disorder event (NCDE) cases reported with statins as the suspected drugs...
January 26, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38269529/efficacy-of-pharmacological-agents-for-the-management-of-treatment-resistant-schizophrenia-a-network-meta-analysis
#24
REVIEW
Archana Mishra, Rituparna Maiti, Biswa Ranjan Mishra, Anand Srinivasan
OBJECTIVE: The present network meta-analysis (NMA) was conducted to compare and generate evidence for the most efficacious treatment among available pharmacological interventions for treatment-resistant schizophrenia (TRS). METHODS: Reviewers extracted data from 47 studies screened from PubMed/MEDLINE, Embase, Cochrane databases and clinical trial registries fulfilling the eligibility criteria. Random effects Bayesian NMA was done with non-informative priors. Network geometry was visualized, and node splitting was done for the closed triangles...
January 25, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38265050/revolutionizing-diabetes-care-unveiling-tirzepatide-s-potential-in-glycemic-control-and-beyond
#25
REVIEW
Aayushi Sood, Purnoor Kaur, Omar Syed, Akshit Sood, Wilbert S Aronow, Benjamin Borokhovsky, Vishal Bhatia, Rahul Gupta
INTRODUCTION: Diabetes is a global public health challenge with rising prevalence. This review explores current diabetes understanding, diagnostic and management guidelines, economic impact, and lifestyle modifications as the primary approach. AREAS COVERED: Focusing on pharmacological interventions, we discuss the roles of GLP-1 agonists and GLP/GIP agonists in diabetes management and cardiovascular risk reduction. Tirzepatide, a novel medication, is highlighted for its unique mechanism of action...
January 24, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38247657/a-preliminary-study-on-plasma-concentration-short-term-efficacy-and-safety-profile-of-dolutegravir-in-chinese-people-with-hiv
#26
JOURNAL ARTICLE
Dongsheng Li, Ran Xiao, Qiang Fu, Xiaojing Song, Yang Han, Xiaoli Du, Taisheng Li
BACKGROUND: This study examined the plasma concentration, clinical efficacy, and safety of dolutegravir (DTG) in Chinese people with HIV(PWH). METHODS: In this observational study, HIV-positive individuals on DTG-based regimens for at least six months were included. Plasma DTG concentrations were measured one month after initiating treatment. Viral loads (VL) and CD4+ T cell counts were evaluated at baseline and after one and six months of therapy. High-performance liquid chromatography was used for measuring DTG concentrations, polymerase chain reaction for VL, and flow cytometry for CD4+ T cell counts...
January 22, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38247431/next-generation-sequencing-in-pharmacogenomics-fit-for-clinical-decision-support
#27
REVIEW
Yitian Zhou, Volker M Lauschke
INTRODUCTION: The technological advances of sequencing methods during the past 20 years have fuelled the generation of large amounts of sequencing data that comprise common variations, as well as millions of rare and personal variants that would not be identified by conventional genotyping. While comprehensive sequencing is technically feasible, its clinical utility for guiding personalized treatment decisions remains controversial. AREAS COVERED: We discuss the opportunities and challenges of comprehensive sequencing compared to targeted genotyping for pharmacogenomic applications...
January 22, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38345044/therapeutic-drug-monitoring-of-imatinib-how-far-are-we-in-the-leukemia-setting
#28
REVIEW
Anna Sofie Buhl Rasmussen, Christen Lykkegaard Andersen, Allan Weimann, Tianwu Yang, Camille Tron, Virginie Gandemer, Kim Dalhoff, Cecilie Utke Rank, Kjeld Schmiegelow
INTRODUCTION: Tyrosine kinase inhibitors (TKIs) have revolutionized survival rates of chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) and replaced hematopoietic stem cell transplantation (hSCT) as the key treatment option for these patients. More recently, the so-called Philadelphia chromosome-like (Ph-like) ALL has similarly benefitted from TKIs. However, many patients shift from the first generation TKI, imatinib, due to treatment-related toxicities or lack of treatment efficacy...
March 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38294680/the-effect-of-different-levothyroxine-administration-regimens-on-thyroid-hormone-levels-a-systematic-review-pairwise-and-network-meta-analysis
#29
REVIEW
Bianca Vendruscolo Bianchini, Patricia Romualdo de Jesus, Renato Gorga Bandeira de Mello, Patricia Klarmann Ziegelmann, Kristian Bellevue Filion, Tatiane da Silva Dal Pizzol
INTRODUCTION: This systematic review aimed to compare the effect of alternative levothyroxine administration regimens on thyroid hormone levels and patient-reported outcomes (PROs) among adults with hypothyroidism. METHODS: We searched PubMed, Embase, CENTRAL, CINAHL, LILACS, SciELO, Scopus, Web of Science, OpenGrey, ProQuest, ClinicalTrials.gov, and ICTRP from inception to May/2023 for randomized controlled trials (RCTs). We assessed the risk of bias with Cochrane Risk of Bias 2...
March 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38224017/comparative-effectiveness-and-safety-of-inhaled-corticosteroid-plus-long-acting-%C3%AE-2-agonist-fixed-dose-combinations-vs-long-acting-muscarinic-antagonist-in-bronchiectasis
#30
JOURNAL ARTICLE
Vincent Yi-Fong Su, Ting-Lin Ding, Yuh-Lih Chang, Yueh-Ching Chou, Hsuen-En Hwang, Chian-Ying Chou, Chia-Chen Hsu
BACKGROUND: This study aimed to evaluate the effectiveness and safety of fixed-dose combination (FDC) inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) in bronchiectasis. RESEARCH DESIGN AND METHODS: A retrospective cohort study analyzed electronic medical records of bronchiectasis patients initiating ICS/LABA FDC or LAMA between 2007 and 2021. All bronchiectasis diagnoses were made by radiologists using high-resolution computed tomography. RESULTS: Of the 1,736 patients, 1,281 took ICS/LABA FDC and 455 LAMA...
January 15, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38217408/biomarker-discovery-in-acetaminophen-hepatotoxicity-leveraging-single-cell-transcriptomics-and-mechanistic-insight
#31
REVIEW
David S Umbaugh, Hartmut Jaeschke
INTRODUCTION: Acetaminophen (APAP) overdose is the leading cause of drug-induced liver injury and can cause a rapid progression to acute liver failure (ALF). Therefore, the identification of prognostic biomarkers to determine which patients will require a liver transplant is critical for APAP-induced ALF. AREAS COVERED: We begin by relating the mechanistic investigations in mouse models of APAP hepatotoxicity to the human APAP overdose pathophysiology. We draw insights from the established sequence of molecular events in mice to understand the progression of events in the APAP overdose patient...
January 13, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38217374/an-update-on-the-clinical-pharmacology-of-kratom-uses-abuse-potential-and-future-considerations
#32
REVIEW
Christopher R McCurdy, Abhisheak Sharma, Kirsten E Smith, Charles A Veltri, Stephanie T Weiss, Charles M White, Oliver Grundmann
INTRODUCTION: Kratom (Mitragyna speciosa) has generated substantial clinical and scientific interest as a complex natural product. Its predominant alkaloid mitragynine and several stereoisomers have been studied for activity at opioid, adrenergic, and serotonin receptors. While awaiting clinical trial results, the pre-clinical evidence suggests a range of potential therapeutic applications for kratom with careful consideration of potential adverse effects. AREAS COVERED: The focus of this review is on the pharmacology, pharmacokinetics, and potential drug-drug interactions of kratom and its individual alkaloids...
January 13, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38197873/artificial-intelligence-based-model-for-dose-prediction-of-sertraline-in-adolescents-a-real-world-study
#33
JOURNAL ARTICLE
Ran Fu, Ze Yu, Chunhua Zhou, Jinyuan Zhang, Fei Gao, Donghan Wang, Xin Hao, Xiaolu Pang, Jing Yu
BACKGROUND: Variability exists in sertraline pharmacokinetic parameters in individuals, especially obvious in adolescents. We aimed to establish an individualized dosing model of sertraline for adolescents with depression based on artificial intelligence (AI) techniques. METHODS: Data was collected from 258 adolescent patients treated at the First Hospital of Hebei Medical University between December 2019 to July 2022. Nine different algorithms were used for modeling to compare the prediction abilities on sertraline daily dose, including XGBoost, LGBM, CatBoost, GBDT, SVM, ANN, TabNet, KNN, and DT...
January 10, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38197151/clinical-trial-design-for-assessing-hypertension-medications-are-critical-circadian-chronopharmacological-principles-being-taking-into-account
#34
JOURNAL ARTICLE
Ramón C Hermida, Michael H Smolensky, Artemio Mojón, José R Fernández
INTRODUCTION: Clinical hypertension trials typically rely on homeostatic principles, including single time-of-day office blood pressure (BP) measurements (OBPM), rather than circadian chronopharmacological principles, including ambulatory monitoring (ABPM) done around-the-clock to derive the asleep systolic BP (SBP) mean and sleep-time relative SBP decline - jointly the strongest prognosticators of cardiovascular disease (CVD) risk and true definition of hypertension - to qualify participants and assess outcomes...
January 10, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38192241/the-future-of-pharmacology-education-a-global-outlook
#35
EDITORIAL
Clare Guilding, Roisin Kelly-Laubscher, Paul White
No abstract text is available yet for this article.
January 9, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38165148/artificial-intelligence-and-machine-learning-in-clinical-pharmacological-research
#36
JOURNAL ARTICLE
Benjamin Mayer, Dario Kringel, Jörn Lötsch
BACKGROUND: Clinical pharmacology research has always involved computational analysis. With the abundance of drug-related data available, the integration of artificial intelligence (AI) and machine learning (ML) methods has emerged as a promising way to enhance clinical pharmacology research. METHODS: Based on an accepted definition of clinical pharmacology as a field of research dealing with all aspects of drug-human interactions, the analysis included publications from institutes specializing in clinical pharmacology...
January 2, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38269492/metformin-adverse-event-profile-a-pharmacovigilance-study-based-on-the-fda-adverse-event-reporting-system-faers-from-2004-to-2022
#37
JOURNAL ARTICLE
Yikuan Du, Jinfeng Zhu, Zhuoming Guo, Zhenjie Wang, Yuni Wang, Mianda Hu, Lingzhi Zhang, Yurong Yang, Jinjin Wang, Yixing Huang, Peiying Huang, Mianhai Chen, Bo Chen, Chun Yang
BACKGROUND: Metformin has the potential for treating numerous diseases, but there are still many unrecognized and unreported adverse events (AEs). METHODS: We selected data from the United States FDA Adverse Event Reporting System (FAERS) database from the first quarter (Q1) of 2004 to the fourth quarter (Q4) of 2022 for disproportionality analysis to assess the association between metformin and related adverse events. RESULTS: In this study 10,500,295 case reports were collected from the FAERS database, of which 56,674 adverse events related to metformin were reported...
2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38131668/population-pharmacokinetics-of-antibacterial-agents-in-the-older-population-a-literature-review
#38
REVIEW
Hui-Xin Liu, Bo-Hao Tang, John van den Anker, Guo-Xiang Hao, Wei Zhao, Yi Zheng
INTRODUCTION: Older individuals face an elevated risk of developing bacterial infections. The optimal use of antibacterial agents in this population is challenging because of age-related physiological alterations, changes in pharmacokinetics (PK) and pharmacodynamics (PD), and the presence of multiple underlying diseases. Therefore, population pharmacokinetics (PPK) studies are of great importance for optimizing individual treatments and prompt identification of potential risk factors...
December 22, 2023: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38108102/set-and-setting-predict-psychopathology-wellbeing-and-meaningfulness-of-psychedelic-experiences-a-correlational-study
#39
JOURNAL ARTICLE
Lucas F Borkel, Jaime Rojas-Hernández, Luis Alberto Henríquez-Hernández, Ángelo Santana Del Pino, Domingo J Quintana-Hernández
BACKGROUND: In psychedelic therapy, the importance of set and setting is a fundamental but under-researched assumption. The aim of this study is to correlate variables of set (psychedelic use motivation) and setting (psychedelic use location and type of companion) with psychopathology, wellbeing and personality variables. RESEARCH DESIGN AND METHODS: A sample of 1022 participants of the Spanish-speaking population was collected through an online survey. A novel instrument, the Psychedelic Use Scale (PUS), was developed to measure substance use variables of LSD, mescaline, psilocybin, DMT, 5-Meo-DMT, ketamine, Salvia divinorum , ibogaine and MDMA...
December 18, 2023: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38108086/insights-into-the-population-pharmacokinetics-and-pharmacodynamics-of-quetiapine-a-systematic-review
#40
REVIEW
Lu Han, Jia-Qin Gu, Jue-Hui Mao, Xiao-Qin Liu, Zheng Jiao
INTRODUCTION: Quetiapine exhibits notable pharmacokinetic and pharmacodynamic (PK/PD) variability, the origins of which are poorly understood. This systematic review summarizes published population PK/PD studies and identifies significant covariates accounting for this variability to inform precision dosing. METHODS: We systematically searched the PubMed, Web of Science, and Embase databases and compared study characteristics, model parameters, and covariate effects...
December 18, 2023: Expert Review of Clinical Pharmacology
journal
journal
41405
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.